53 related articles for article (PubMed ID: 22753908)
1. Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations.
Moran T; Sequist LV
J Clin Oncol; 2012 Sep; 30(27):3330-6. PubMed ID: 22753908
[No Abstract] [Full Text] [Related]
2. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.
Heuckmann JM; Rauh D; Thomas RK
J Clin Oncol; 2012 Sep; 30(27):3417-20. PubMed ID: 22915655
[No Abstract] [Full Text] [Related]
3. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
[TBL] [Abstract][Full Text] [Related]
4. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
Yu Z; Boggon TJ; Kobayashi S; Jin C; Ma PC; Dowlati A; Kern JA; Tenen DG; Halmos B
Cancer Res; 2007 Nov; 67(21):10417-27. PubMed ID: 17974985
[TBL] [Abstract][Full Text] [Related]
5. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis?
Wierzbicka E; Tourani JM; Guillet G
Br J Dermatol; 2006 Jul; 155(1):213-4. PubMed ID: 16792781
[No Abstract] [Full Text] [Related]
6. EGFR inhibitors: what have we learned from the treatment of lung cancer?
Giaccone G; Rodriguez JA
Nat Clin Pract Oncol; 2005 Nov; 2(11):554-61. PubMed ID: 16270096
[TBL] [Abstract][Full Text] [Related]
7. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
8. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ
Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260
[TBL] [Abstract][Full Text] [Related]
9. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone T; Gridelli C; Ciardiello F
Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
[TBL] [Abstract][Full Text] [Related]
10. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.
Kasahara K; Arao T; Sakai K; Matsumoto K; Sakai A; Kimura H; Sone T; Horiike A; Nishio M; Ohira T; Ikeda N; Yamanaka T; Saijo N; Nishio K
Clin Cancer Res; 2010 Sep; 16(18):4616-24. PubMed ID: 20679350
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced effects on erlotinib metabolism.
Mir O; Blanchet B; Goldwasser F
N Engl J Med; 2011 Jul; 365(4):379-80. PubMed ID: 21793762
[No Abstract] [Full Text] [Related]
13. Treatment of the future, today?
Schneider BJ
J Clin Oncol; 2012 Nov; 30(32):4035-6. PubMed ID: 23008328
[No Abstract] [Full Text] [Related]
14. Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor.
Dainichi T; Tanaka M; Tsuruta N; Furue M; Noda K
Dermatology; 2003; 207(3):324-5. PubMed ID: 14571080
[No Abstract] [Full Text] [Related]
15. Blepharitis induced by epidermal growth factor receptor-targeting therapy.
Ulusakarya A; Gumus Y; Delmas-Marsalet B; Machover D
Am J Clin Oncol; 2006 Oct; 29(5):531. PubMed ID: 17023793
[No Abstract] [Full Text] [Related]
16. Commentary to Pastore et al. (2014): epidermal growth factor receptor signaling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors.
Takeda K; Kawamoto Y; Iida M; Omata Y; Zou C; Kato M
Arch Toxicol; 2014 Dec; 88(12):2319-20. PubMed ID: 25248502
[No Abstract] [Full Text] [Related]
17. Replica to K. Takeda et al. Commentary to Pastore et al. (2014): epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors.
Pastore S; Lulli D; Girolomoni G
Arch Toxicol; 2014 Dec; 88(12):2321-2. PubMed ID: 25370012
[No Abstract] [Full Text] [Related]
18. Tyrosine Kinase Receptors in Oncology.
Esteban-Villarrubia J; Soto-Castillo JJ; Pozas J; San Román-Gil M; Orejana-Martín I; Torres-Jiménez J; Carrato A; Alonso-Gordoa T; Molina-Cerrillo J
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198314
[TBL] [Abstract][Full Text] [Related]
19. Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies.
Biteghe FAN; Mungra N; Chalomie NET; Ndong JC; Engohang-Ndong J; Vignaux G; Padayachee E; Naran K; Barth S
Oncotarget; 2020 Sep; 11(38):3531-3557. PubMed ID: 33014289
[TBL] [Abstract][Full Text] [Related]
20. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.
Li Z; Wang M; Yao X; Luo W; Qu Y; Yu D; Li X; Fang J; Huang C
Target Oncol; 2019 Feb; 14(1):93-105. PubMed ID: 30635821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
